As BAY2927088 enters phase 3 its lung cancer use will no longer be limited to exon 20.

The company defends its cancer strategy, and says it's not a me-too developer.

Tagrisso is a knockout on PFS, but only OS will show whether it should be given before patients progress.

Meanwhile, Lilly gets in on the next-gen KRAS action.

The PD-1 x VEGF bispecific apparently bests Keytruda, but questions remain.

Gilead came out swinging in second-line lung cancer, but it might have just whiffed.

Paloma-3 data suggest subcutaneous Rybrevant might have an edge over the intravenous formulation.

Eagerly awaited data with the anti-PD-L1 x 4-1BB bispecific acasunlimab raise liver toxicity concerns.